Tag: bemcentinib

April 2, 2019 Off

BergenBio shows bemcentinib’s potential to reverse tumour immunosuppression and therapy resistance

BergenBio said Tuesday that preclinical data strengthen bemcentinib’s potential in reversing tumour-mediated immunosuppression and therapy resistance, ina presentation by its academic collaborators at the American Association for Cancer Research (AACR) Annual Meeting 2019.

January 4, 2019 Off

BerGenBio doses first patient in Phase II monotherapy study of bemcentinib in high-risk MDS & AML

By Dino Mustafić

BerGenBio ASA has been dosed the first patient with bemcentinib, in an investigator-initiated phase II trial, sponsored by GWT-TUD GmbH, a specialist cancer clinical research institution associated with the University of Dresden, Germany.